CymaBay Therapeutics Inc (CBAY) Director Purchases $999,999.00 in Stock

CymaBay Therapeutics Inc (NASDAQ:CBAY) Director Kurt Von Emster acquired 153,846 shares of CymaBay Therapeutics stock in a transaction on Thursday, July 19th. The shares were purchased at an average price of $6.50 per share, with a total value of $999,999.00. Following the completion of the purchase, the director now owns 90,000 shares in the company, valued at approximately $585,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kurt Von Emster also recently made the following trade(s):

  • On Wednesday, February 7th, Kurt Von Emster sold 40,763 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $12.35, for a total transaction of $503,423.05.
  • On Monday, February 5th, Kurt Von Emster sold 18,831 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $12.14, for a total transaction of $228,608.34.
  • On Friday, February 2nd, Kurt Von Emster sold 90,098 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $12.15, for a total transaction of $1,094,690.70.
  • On Wednesday, January 31st, Kurt Von Emster sold 97,639 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $12.22, for a total transaction of $1,193,148.58.
  • On Thursday, January 25th, Kurt Von Emster sold 39,438 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $12.18, for a total transaction of $480,354.84.
  • On Monday, January 22nd, Kurt Von Emster sold 138,253 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $10.40, for a total transaction of $1,437,831.20.
  • On Friday, January 19th, Kurt Von Emster sold 144,216 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $10.25, for a total transaction of $1,478,214.00.
  • On Friday, January 5th, Kurt Von Emster sold 4,300 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $10.21, for a total transaction of $43,903.00.
  • On Friday, December 22nd, Kurt Von Emster sold 173,192 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $9.41, for a total transaction of $1,629,736.72.

CymaBay Therapeutics Inc (CBAY) traded up $0.54 on Monday, hitting $12.25. 644,992 shares of the company were exchanged, compared to its average volume of 921,120. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.39 and a current ratio of 7.39. The stock has a market capitalization of $513.65, a P/E ratio of -12.13 and a beta of 2.04. CymaBay Therapeutics Inc has a one year low of $2.31 and a one year high of $13.25.

A number of analysts have recently issued reports on the stock. ValuEngine raised shares of CymaBay Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. BidaskClub raised shares of CymaBay Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, January 26th. Roth Capital reaffirmed a “buy” rating and set a $27.00 price target on shares of CymaBay Therapeutics in a report on Thursday, January 25th. Zacks Investment Research raised shares of CymaBay Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, January 26th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target (up previously from $12.00) on shares of CymaBay Therapeutics in a report on Wednesday, January 24th. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. CymaBay Therapeutics has a consensus rating of “Buy” and an average target price of $16.56.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Boothbay Fund Management LLC purchased a new position in shares of CymaBay Therapeutics in the third quarter worth approximately $404,000. Perceptive Advisors LLC purchased a new position in shares of CymaBay Therapeutics in the third quarter worth approximately $18,948,000. Bank of New York Mellon Corp boosted its holdings in shares of CymaBay Therapeutics by 794.7% in the third quarter. Bank of New York Mellon Corp now owns 155,174 shares of the biopharmaceutical company’s stock worth $1,251,000 after buying an additional 137,830 shares during the last quarter. Ardsley Advisory Partners boosted its holdings in shares of CymaBay Therapeutics by 66.2% in the second quarter. Ardsley Advisory Partners now owns 50,210 shares of the biopharmaceutical company’s stock worth $290,000 after buying an additional 20,000 shares during the last quarter. Finally, EAM Investors LLC purchased a new position in shares of CymaBay Therapeutics in the third quarter worth approximately $4,788,000. 54.80% of the stock is currently owned by institutional investors.

WARNING: “CymaBay Therapeutics Inc (CBAY) Director Purchases $999,999.00 in Stock” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/12/cymabay-therapeutics-inc-cbay-director-purchases-999999-00-in-stock.html.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Insider Buying and Selling by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply